Skip to main content

Seryx Licenses Pharmacogenetics Technology to Asian Joint Venture

NEW YORK, Feb. 6 (GenomeWeb News) - Bioinformatics company Seryx has licensed its pharmacogenetics technology to an Asian joint venture, the company said yesterday.


Under the agreement, Singapore-based Seryx Asia, which is owned by both Seryx and Iprex Asia Pacific, obtains the exclusive right to commercialize Seryx's technology in Thailand, Singapore, Hong Kong, Malaysia, Australia, and New Zealand.


Seryx, based in Cherry Hill, NJ, offers genetic and medical history analysis.


The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.